四環醫藥：中期報告2019.pdf

1、2019中期報告INTERIM REPORT 公司簡介CORPORATE PROFILEFounded in 2001,Sihuan Pharmaceutical Holdings Group Ltd(“Sihuan Pharmaceutical”or the“Company”),together with its subsidiaries(the“Group”)has become the largest cardio-cerebral vascular(“CCV”)drug manufacturer in Chinas prescription drug market by market

2、share since 2007.Sihuan Pharmaceutical is an integrated corporate with its own production,research and development(“R&D”)and marketing capacities.The success of the Group can be attributed to its differentiated and proven sales and marketing model,extensive nationwide distribution network,diversifie

3、d product portfolio,and strong R&D capabilities.The Group has begun its innovative drug R&D since 2008 and now possesses a well-established innovative and generic drug R&D platform,which is supported by approximately 600 R&D experts and focuses in therapeutic areas with considerable unmet clinical d

4、emand.The Groups current products and R&D pipeline encompass the top five medical therapeutic areas:cardio-cerebral vascular system,central nervous system,metabolism,oncology and anti-infectives.四環醫藥控股集團有限公司（四環醫藥或 本公司），連同其附屬公司為（本集團）成立於二零零一年，自二零零七年起，成為全國最大的心腦血管（心腦血管）處方藥物供應商。四環醫藥為生產、研究與開發（研發）、營銷一體的醫藥公

5、司。本集團的成功是由於擁有優秀的行銷模式及覆蓋全國的分銷網路、具市場潛力的多元化產品組合，以及強大的研發實力。本集團於二零零八年開始投入創新藥研發，擁有約600名研發人員組成的領先的研發團隊，已建立了成熟的創新藥和仿制藥研發平台，專注於具有重大臨床需求的治療領域。本集團目前銷售產品及在研發產品線涵蓋五大醫療領域：心臟血管系統、中樞神經系統、新陳代謝、腫瘤及抗感染。目錄CONTENTS02公司資料Corporate Information04管理層討論及分析Management Discussion and Analysis30其他資料Other Information47獨立審閱報告Indep

6、endent Review Report49中期簡明綜合財務狀況表Interim Condensed Consolidated Statement of Financial Position52中期簡明綜合損益及其他全面收益表Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income54中期簡明綜合權益變動表Interim Condensed Consolidated Statement of Changes in Equity56中期簡明綜合現金流量表Interim Con